Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The base Gland business posted ?11,790 million in revenue, up 16% YoY
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
The new functionality complements Parse’s existing Evercode immune products
Company to launch product after the expiry of semaglutide patent in India
Subscribe To Our Newsletter & Stay Updated
